ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neuromuscular Disorders and Peripheral Neuropathies
Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States
Provisionally accepted
Cécile Blein1Chafic Karam2Clémence Arvin-Berod1Deborah Gelinas3Sergio Barrera-Sierra1Hashmath Ulla T A Syed4
Charlotte E Ward3*Amit Goyal5Jeffrey Guptill3- 1argenx BVBA, Ghent, Belgium
- 2University of Pennsylvania, Philadelphia, United States
- 3argenx US Inc, Boston, United States
- 4ZS Associates, Bengaluru, India
- 5ZS Associates, Princeton, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Management of chronic inflammatory demyelinating polyneuropathy (CIDP) is challenged by heterogeneity in severity, comorbidities, potential adverse effects, and treatment accessibility. This study aimed to elucidate treatment utilization among patients with CIDP in the United States (US) to identify potential unmet needs. Methods: Adult patients with CIDP were identified using Komodo Health's Healthcare MapTM (January 2016–December 2020). Descriptive statistics related to utilization of CIDP treatments over 1-year post-index were analyzed. Among patients who used immunoglobulin (Ig), chronic Ig users were defined as patients with ≥8 Ig courses, and intermittent Ig users as patients with <8 Ig courses during 1-year post-index. Results: Among 3409 patients with CIDP identified, the majority (81% [n = 2758]) were treated for CIDP while 19% (n = 651) were untreated for CIDP during 1-year post-index. Steroids (73% [n = 2017]) followed by Ig (65% [n = 1803]) were most commonly utilized. Of patients who used Ig, 62% (n = 1113) were chronic and 38% (n = 690) were intermittent users during the 1-year post-index. A large proportion of Ig users received concomitant CIDP treatments, most commonly steroids. Patients who received >60 mg/day oral steroids on average over the 1-year post-index continued to use concomitant CIDP treatment, most commonly Ig. Conclusion: Steroids and Ig were mainstay treatments among patients with CIDP. A substantial proportion of Ig users were chronic users who also received other CIDP therapies, with steroids being most common. This suggests a potentially pronounced burden among patients treated with frequent Ig and steroids.
Keywords: Chronic inflammatory demyelinating polyradiculoneuropathy, immunoglobulin, Immunoglobulin (Ig), Real-world evidence, treatment utilization
Received: 17 Oct 2025; Accepted: 05 Dec 2025.
Copyright: © 2025 Blein, Karam, Arvin-Berod, Gelinas, Barrera-Sierra, Syed, Ward, Goyal and Guptill. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Charlotte E Ward
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.